Kontić, M.; Marković, F.; Nikolić, N.; Samardžić, N.; Stojanović, G.; Simurdić, P.; Petkov, S.; Bursać, D.; Zarić, B.; Stjepanović, M.
Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data. Cancers 2024, 16, 3696.
https://doi.org/10.3390/cancers16213696
AMA Style
Kontić M, Marković F, Nikolić N, Samardžić N, Stojanović G, Simurdić P, Petkov S, Bursać D, Zarić B, Stjepanović M.
Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data. Cancers. 2024; 16(21):3696.
https://doi.org/10.3390/cancers16213696
Chicago/Turabian Style
Kontić, Milica, Filip Marković, Nikola Nikolić, Natalija Samardžić, Goran Stojanović, Petar Simurdić, Svetlana Petkov, Daliborka Bursać, Bojan Zarić, and Mihailo Stjepanović.
2024. "Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data" Cancers 16, no. 21: 3696.
https://doi.org/10.3390/cancers16213696
APA Style
Kontić, M., Marković, F., Nikolić, N., Samardžić, N., Stojanović, G., Simurdić, P., Petkov, S., Bursać, D., Zarić, B., & Stjepanović, M.
(2024). Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data. Cancers, 16(21), 3696.
https://doi.org/10.3390/cancers16213696